{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:04:27Z","timestamp":1790877867083,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,1,9]],"date-time":"2007-01-09T00:00:00Z","timestamp":1168300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Steroid\u2010induced rosacea\u2010like eruption is characterized by facial rosacea\u2010like dermatitis in patients that have been treated with topical steroids for relatively long periods.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To evaluate the efficacy and tolerability of 1% pimecrolimus topical cream for steroid\u2010induced rosacea\u2010like eruption.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In an open\u2010label pilot study, 40 patients were enrolled and instructed to apply 1% pimecrolimus cream twice daily for 6\u00a0weeks. Patients were evaluated by a rosacea clinical score, investigator's global assessment, overall erythema severity, and tolerability at weeks 0, 2, and 6.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> In 35 patients, the rosacea clinical score decreased significantly from 16.0\u00a0\u00b1\u00a04.3 at baseline to 8.1\u00a0\u00b1\u00a03.3 at week 2 and 4.2\u00a0\u00b1\u00a02.5 at week 6 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). Investigator's global assessment was 4.1\u00a0\u00b1\u00a01.1 (baseline), then decreased to 1.4\u00a0\u00b1\u00a00.8 (week 2) and 0.5\u00a0\u00b1\u00a00.6 (week 6) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). By week 6, 48.6% of the patients were clear. Overall erythema severity was 2.4\u00a0\u00b1\u00a00.7 (baseline), 0.9\u00a0\u00b1\u00a00.4 (week 2), and 0.3\u00a0\u00b1\u00a00.4 (week 6) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). Cutaneous adverse events (local burning, stinging, and itching) occurred in 17.5%.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Pimecrolimus cream might be efficacious, safe, and well tolerated for steroid\u2010induced rosacea\u2010like eruption. The small sample size and open label nature of this study is its limitation. Further double\u2010blind, vehicle\u2010controlled studies are needed.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.01991.x","type":"journal-article","created":{"date-parts":[[2007,1,9]],"date-time":"2007-01-09T22:22:34Z","timestamp":1168381354000},"page":"484-490","source":"Crossref","is-referenced-by-count":30,"title":["An open\u2010label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid\u2010induced rosacea\u2010like eruption"],"prefix":"10.1111","volume":"21","author":[{"given":"C\u2010Y","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,3,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5645.670"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1974.01630100075019"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2002.00388_2.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.110.1.e2","article-title":"Efficacy and safety of pimecrolimus cream in the long\u2010term management of atopic dermatitis in children","volume":"110","author":"Wahn U","year":"2002","journal-title":"Pediatrics"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065863"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)73849-6"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119648"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114739"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02157-1"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06404.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2005.03740.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13357"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00587.2004"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70065-2"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.2.229"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071800"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.4.457"},{"issue":"3","key":"e_1_2_5_22_2","first-page":"183","article-title":"Comparison of pimecrolimus cream 1% and tacrolimus ointment 0.03% in paediatric patients with atopic eczema","volume":"17","author":"Kempers S","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.01991.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.01991.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:38:35Z","timestamp":1696981115000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.01991.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,5]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1468-3083.2006.01991.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01991.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,5]]}}}